Article Figures & Data
Figures
- FIGURE 1.
Maximum-intensity-projection (A), transaxial PET (B), and transaxial CT (C) images of 67-y-old man with calcitonin level of 119,000 pg/mL. Maximum-intensity projection shows multiple foci of 18F-FDG uptake in neck, mediastinum, and lungs. 18F-FDG PET and CT show metastatic mediastinal lymph nodes (arrows).
- FIGURE 2.
Distribution of 18F-FDG PET findings in relation to calcitonin levels. (A) Box plot shows range of calcitonin levels in 18F-FDG PET–positive vs. 18F-FDG PET–negative scans. (B) Scattergram shows distribution of highest SUV per study in relation to calcitonin levels.
- FIGURE 3.
(A) Transaxial contrast-enhanced CT image of 51-y-old woman with calcitonin level of 48,800 pg/mL shows hepatic metastasis (arrow). (B) Coronal 18F-FDG PET image of same patient shows no appreciable abnormal uptake.
Tables
Patient no. Scan no. Time from TT to PET (mo) Calcitonin (pg/mL) CEA (ng/mL) PET findings (with maximum SUV of representative regions in parentheses) Correlative imaging Bx/Ex PET classification 1 1 16 994 5.3 — None None FN 2 26 8,330 NA R neck (3.2) None Ex+ TP 2 1 9 316 NA — CT neck/chest− SRS− None FN 3 1 17 3,687 NA R neck (4.1), R hilum (4.2) CT neck/chest+ Ex+ TP 2 26 514 NA Bil hilum (3.3) CT chest+ None TP 4 1 13 54,945 535.1 Med (2.7) CT chest+ SRS− None TP 5 1 4 15,430 6.4 Med (3.0), L neck (3.0) SRS+ None TP 2 14 21,300 6.8 Med (4.0) None Ex+ TP 6 1 67 5,000 NA — None None FN 2 72 10,790 NA Thyroid bed (4.6) None Ex+ TP 3 76 36,670 NA — None None FN 4 88 55,200 137.6 — SRS− None FN 5 102 176,000 802.2 L neck (3.4) CT neck+ Ex+ TP 6 108 541,000 NA Liver (3.5), ab node (5.5) CT neck/chest/ab+ None TP 7 1 6 862 1 — CT neck− None FN 2 16 1,420 1.4 — CT neck− None FN 8 1 60 1,330 NA R neck (4.8), L neck (3.9) US+ SRS− None TP 9 1 48 15,300 NA L neck (2.7) CT neck+ None TP 10 1 6 6,190 2.3 — US+ Ex+ FN 11 1 6 106 4.3 — CT neck− None FN 12 1 27 16,600 57.1 R neck (2.0), med (3.0) US+ Ex+ TP 13 1 34 189,100 907 Bone (3.3), liver (4.2) CT neck/chest/ab+ None TP 14 1 144 48,800 NA — CT chest/ab+ None FN 15 1 33 1,960 4.5 Thyroid bed (3.9), R neck (3.4) CT neck+ Ex+ TP 16 1 46 47,850 NA L neck (3.7), med (5.5), lung (3.8), liver (8.3) CT neck+ Bx+ TP 17 1 3 49,600 133.7 Thyroid bed (11.5), bil neck (15.1), med (15.9), bone (6.4) None None TP 18 1 >240 130,300 306.2 Thyroid bed (6.0), bone (6.3), liver (4.2) CT neck/chest+ MRI spine+ Ex+ TP 19 1 >144 518 NA Thyroid bed (3.3), R neck (4.8), bil axilla (7.8), med (5.2), lung (4.8) CT neck/chest+ None TP 20 1 16 4,520 10.4 Thyroid bed (4.6) CT neck+ Ex+ TP 21 1 72 931 NA — None None FN 22 1 4 509 3.3 — CT neck/chest/ab− None FN 23 1 1 1,212 NA R neck (4.8) MRI neck+ Ex+ TP 2 10 381 NA — None None FN 24 1 1 230 NA — CT neck− None FN 25 1 1 36,300 4.8 Bil neck (15.0), med (7.8) CT neck+ Ex+ TP 26 1 10 25,000 5.4 L neck (2.5), med (2.9) CT neck/chest+ Ex+ TP 27 1 12 119,000 7.6 Bil neck (7.0), L hilum (5.3), bil lung (5.0), bone (5.4) MRI spine+ Bx+ TP 28 1 >132 563 5.9 Liver (5.9) CT ab: HCC Ex: HCC FP ab = abdomen; bil = bilateral; bx = biopsy; CEA = carcinoembryonic antigen; ex = excision; FN = false-negative; FP = false-positive; HCC = hepatocellular carcinoma; med = mediastinum; NA = not available; SRS = somatostatin receptor scintigraphy; TP = true-positive; TT = total thyroidectomy; US = ultrasound neck.
Jump to section
Related Articles
Cited By...
- Patient-Derived Medullary Thyroid Cancer Organoids; a Model for Patient-tailored Drug and PET-Tracer Screening
- A review of diagnostic approaches to medullary thyroid carcinoma
- Predictive Value of 18F-FDG PET in Patients with Advanced Medullary Thyroid Carcinoma Treated with Vandetanib
- Current Understanding and Management of Medullary Thyroid Cancer
- NCCN Task Force: Clinical Utility of PET in a Variety of Tumor Types
- 18F-Dihydroxyphenylalanine PET in Patients with Biochemical Evidence of Medullary Thyroid Cancer: Relation to Tumor Differentiation
- Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times
- Would Patient Selection Based on Both Calcitonin Blood Level and Doubling Time Improve 18F-FDG PET Sensitivity in Restaging of Medullary Thyroid Cancer?
- Reply: Would Patient Selection Based on Both Calcitonin Blood Level and Doubling Time Improve 18F-FDG PET Sensitivity in Restaging of Medullary Thyroid Cancer?